Interesting new study presented at European Academy of Neurology (EAN) 2018
"Increasing evidence suggests that the levels of a protein called neurofilament light chain (NfL) are increased in the blood and cerebrospinal fluid of patients with multiple sclerosis (MS)."

Read about how the levels of neurofilament light chain (NfL) are a reliable biomarker of disease worsening and progression in RRMS patients, and how Gilenya treatment can reduce its levels for up to 10 years.